The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world outcomes in patients with metastatic renal cell carcinoma (mRCC) receiving dual immune checkpoint inhibitor (ICI-ICI) regimens or immune checkpoint inhibitor and tyrosine kinase inhibitor (ICI-TKI) combinations as first-line therapy: A British Columbia (BC) population-based analysis.
 
Antoine Morin Coulombe
No Relationships to Disclose
 
Faisal Abdullah Alsadoun
No Relationships to Disclose
 
Xin (Cynthia) Ye
No Relationships to Disclose
 
Maryam Soleimani
Honoraria - Ipsen; Pfizer
Consulting or Advisory Role - Bayer
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bayer (Inst)
 
Lucia Nappi
Honoraria - AstraZeneca; Bayer; Ipsen; Merck Serono; Pfizer
Consulting or Advisory Role - AstraZeneca; Bayer; Ipsen; Pfizer
Research Funding - EMD Serono (Inst); Ipsen (Inst); Janssen Oncology (Inst)
Patents, Royalties, Other Intellectual Property - IVERMECTIN ANALOGUE COMPOUND THERAPEUTICS FOR HEAT SHOCK PROTEIN-27 (HSP27) INHIBITION, METHODS AND USES ASSOCIATED THEREWITH provisional number: 62/756,707
 
Bernhard J. Eigl
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Pfizer; EMD Serono/Merck; Gilead Sciences; Janssen; Pfizer; Roche Canada; Seagen
Consulting or Advisory Role - EMD Serono; Gilead Sciences
Travel, Accommodations, Expenses - EMD Serono
 
Kim N. Chi
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; POINT Biopharma; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Constellation Pharmaceuticals; Daiichi Sankyo; ESSA; Janssen; Merck; POINT Biopharma; Roche; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Expert Testimony - AstraZeneca; Novartis
 
Christian K. Kollmannsberger
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen Oncology; Merck; Merck KGaA; Pfizer
Consulting or Advisory Role - AAA/Endocyte/Novartis; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; Ipsen; Janssen; Merck; Merck KGaA; Pfizer
Travel, Accommodations, Expenses - Ipsen; Janssen Oncology; Pfizer